Hypofractionated Stereotactic Boost in Prostate Cancer

Inclusion Criteria: * Prostate adenocarcinoma proved by histology * With at least one of this intermediate-risk criterias: * T2b * and/or PSA between 10 et 20 ng/ml * and/or Gleason score = 7 * Prostatic volume ≤ 80 cc * No adenopathy(lymph node \< 1.5 cm on scanner or MRI and/or in lymph node dissection) * No metastasis (bone scan) * Age \>= 18 ans * No prior pelvic irradiation * No prior anticancer treatment (prostatectomy, chemotherapy, hormonotherapy \> 3 months) * Performance status (ECOG) \< 1 * No contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation * Life expectancy \>= 10 weeks * Patient affiliated to health insurance * Informed consent signed by the patient Exclusion Criteria: * Cancer no histologically proved * Unfavorable-risk(T2c and/or PSA \> 20 ng/ml and/or Gleason \> 7) * Favorable-risk(T1c T2a and PSA \< 10 ng/ml and Gleason \< 7) * T3 and T4 * History of cancer uncontrolled and/or treated since less of 5 years (except basal cell carcinoma of the skin) * Contraindication to MRI * IPSS score \> 10 * Recurrent or metastatic disease * Allergy to gold * Patient already included in another therapeutic trial with an experimental molecule * Unable for medical follow-up (geographic, social or mental reasons)